Chapter

Operations Research and Health Care Policy

Volume 190 of the series International Series in Operations Research & Management Science pp 251-279

Date:

Active Vaccine and Drug Surveillance

Towards a 100 Million Member System
  • Margrét V. BjarnadóttirAffiliated with Email author 
  • , David CzerwinskiAffiliated with

* Final gross prices may vary according to local VAT.

Get Access

Abstract

After the withdrawal of rofecoxib (known by the trade name Vioxx) from the US pharmaceutical market in 2004, post-approval drug safety and surveillance came under serious scrutiny. In 2008 the FDA announced the Sentinel Initiative, which includes an active surveillance system based on 100 million people’s health-care data. In this chapter we describe a number of challenges involved in active drug and vaccine surveillance and provide an overview of state-of-the-art surveillance methodologies. We also address the statistical tradeo-ffs involved in surveillance, highlight some areas for future research, and frame the policy issues that designers of surveillance systems will have to address.